Bioventus (BVS) Common Equity (2020 - 2026)

Bioventus (BVS) has reported Common Equity for 7 consecutive years, with $277.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 37.81% year-over-year to $277.4 million; the trailing twelve-month figure through Jun 2026 stood at $277.4 million (up 37.81% YoY), and the FY2025 full-year result was $228.4 million, up 23.08% from the prior year.
• Common Equity grew to $277.4 million in Q2 2026 per BVS's latest filing, from $234.3 million in the prior quarter.
• Across five years, Common Equity topped out at $593.8 million in Q2 2022 and bottomed at $185.5 million in Q1 2025.
• Historically, Common Equity has averaged $282.4 million across 5 years, with a median of $227.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 169.91% in 2022, then tumbled 60.59% in 2023.
• Over 5 years, Common Equity stood at $412.2 million in 2022, then sank by 46.36% to $221.1 million in 2023, then fell by 16.06% to $185.6 million in 2024, then rose by 23.08% to $228.4 million in 2025, then increased by 21.43% to $277.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $277.4 million, $234.3 million, and $228.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.